Replies to post #669343 on NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

BP don’t calculate future valuation in their “heart of hearts” nor need they do it based upon market cap premium. They do it based upon future projected sales.

So does every competent retail investor you dumb shit. And NWBO is valued at $700M.

So again, I am telling you, as a matter of fact, that BP will not offer 1000+% premiums for NWBO just because they KNOW that NWBO sales are going to to be in the billions.

The investors have to believe that as well. And if investors believed that, they would be buying NWBO and putting the valuation at a true level. Clearly investors do not believe that, so clearly BP cannot justify a $20B buyout for a company trading at $700M.

You are literally too stupid to have a discussion with.

[Doc logic]

flipper44,

What FeMike is saying is that the right information and the right amount of time can get to what you are talking about but that we must first bridge that gap. The debate being created here is really more about how much time is needed to prove that potential with approvals or revenues and whether or not NWBO can be forced into an unwanted buyout situation at undervalued prices compared to underlying intrinsic value of the platform before then.
I believe much will be revealed once L is approved but that the magnitude of what they are capable of doing will take about 3 years to fully sink in from trials and data from them started later this year and next. Let’s just wait for “the right kind of news” that propels us into the upper trend range by end of Q3 this year as spec value comes into play. Best wishes.